Fig. 9: CDKN2C expression is associated with HBV infection, liver disease, and survival in patients.

a CDKN2C mRNA expression in HBV-infected PHH from 3 different donors quantified by qRT-PCR. Results are expressed as means +/− SEM % relative CDKN2C expression compared to Mock (set to 100%) from 3 independent experiments (n = 9). b CDKN2C expression in HBV-infected patients with undetectable (HBV DNA(−), n = 32) or detectable (HBV DNA(+), n = 90) HBV DNA compared to healthy patients (n = 6) (cohorts described in “Methods”). c CDKN2C expression in HBV-infected patients depending on the stage of virus infection (cohorts described in “Methods”). Tolerance: n = 22; Clearance: n = 50; Inactive: n = 11. d CDKN2C expression in tumor and adjacent tissues in HCC patients from two independent cohorts (see “Methods”). Non-tumor: n = 198; Tumor: n = 98 (left panel). Non-tumor: n = 5; Tumor: n = 50 (right panel). e CDKN2C expression in tumor and non-tumor (normal) liver tissue from patients with alcoholic liver disease (Alc, Tumor: n = 70; Non-tumor: n = 8), HBV-infected patients (Tumor: n = 76; Non-tumor: n = 7), HCV-infected patients (Tumor: n = 34; Non-tumor: n = 5), and patients with non-alcoholic fatty liver disease (NAFLD, Tumor: n = 11; Non-tumor: n = 2) extracted from TCGA database as described in “Methods.” f Survival analysis for HCC patients with low or high CDKN2C expression (for cohort, see “Methods”). *p < 0.05; **p < 0.01; ***p < 0.001 (b, c: Kruskal–Wallis H test adjusted for multiple comparisons; d, e: two-tailed Mann–Whitney U test). The details of the plots are presented in Supplementary Tables 2 and 3. Source data are provided as a Source Data file.